Spine
Medtronic Needs to Regrow a Spine
Medtronic‘s (NYSE: MDT) third-fiscal-quarter revenue chart would make a good preschool test for finding the outlier. (Hint: Look for the parentheses.)
Segment | Sales (in Millions) | Increase (Decrease) at Constant Currencies |
---|---|---|
Cardiac rhythm disease management | $1,243 | 2% |
Spinal | $842 | (1%) |
Cardiovascular | $722 | 21% |
Neuromodulation | $394 | 8% |
Diabetes | $311 | 8% |
Surgical technologies | $239 | 12% |
Physio-control | $100 | 8% |
To read more please CLICK HERE
Source: Company press release.